Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
NCT00810576Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2009
- Primary completion
- Apr 2010
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in T-cell non-Hodgkin lymphoma, sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2009; status: terminated.
02
Drugs
vorinostat
03
Conditions
T-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00810576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00810576.